Pfizer UK will provide subscription access to the Ledidi real-world evidence platform. Ledidi is a GDPR-compliant cloud-based all-in-one platform for collecting, structuring, analysing and visualising data with a built-in mechanism of collaboration between clinicians and institutions. The platform allows for the creation of registries, research projects and multi-centre collaborations with real time statistical analytics. The platform also facilitates the upload of existing data sets into the platform, with functionality which includes the automatic sorting and categorising of these data. The sharing of data between collaborators is controlled by the lead trust and the platform does not limit the number of projects/registries/collaborations.
The Pfizer donation will consist of:
Access to the Ledidi platform with Prime/Core level subscription for 36 months
The subscription will start once the HCP/Trust has created their account with Ledidi
Ledidi can offer personalised onboarding of the users, including support in data privacy support with trust IT, within a reasonable scope
Ledidi will ensure that they continue to provide support for the platform for the duration of the 36 months
Hospital trusts utilising the Ledidi platform will retain ownership and control of any data that is uploaded: neither Pfizer nor Ledidi will be able to access or be privy to any data on the site. All patient level data held on the platform with be anonymised. Any sharing of data by the trust is through their own collaborations either within or outside of the platform and Ledidi is required to maintain adherence to data privacy laws.
Any hospitals within the UK NHS that treats multiple myeloma can to apply for this service donation. Forty subscriptions in total are available and NHS trusts will be selected to receive this donation on a first-come, first-served basis and based on the below criteria:
Treating multiple myeloma patients
At least one member of the hospital team dedicated to helping facilitate the audit including ensuring appropriate local data protection and IT facilitation
NHS hospital expresses intent to share best practice via local or national publication/congress presentation
All applications will be reviewed in order of application date and time on a first-come, first-served basis. Once all subscriptions have been allocated then the application portal will close. If a large number of applications are received all at once then the application portal may close until the backlog of applications is reviewed or until all grants are allocated, whichever occurs first.
All applications will be reviewed by an internal Pfizer medical review panel. Once you have submitted a request, we will also share further information regarding Ledidi Prime/Core. Additional clarification during the review period may be requested. All applicants will be notified via email regarding the outcome of their request, upon completion of the internal review process.
If your application is approved, your institution will be required to enter into a written grant agreement with Pfizer. In the event of a successful application, core terms of the agreement will be provided. Disclosure of this Pfizer donation will be required by each recipient hospital.
For further information on the data privacy and security of the Ledidi Real-World Evidence platform please refer to the following links.
Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. Pfizer accepts no responsibility for the content or services of the linked site.
All applications will be reviewed by an internal Pfizer medical review panel. Once you have submitted a request, we will also share further information regarding Ledidi Core. Additional clarification during the review period may be requested. All applicants will be notified via email regarding the outcome of their request, upon completion of the internal review process.
If your application is approved, your institution will be required to enter into a written grant agreement with Pfizer. In the event of a successful application, core terms of the agreement will be provided at a later date. Disclosure of this Pfizer donation will be required by each recipient hospital.